Nanobiotix Prices $98.6M Global Offering at Discount, Extends Cash Runway to 2029
NBTX has more than doubled off its 52-week low of $3.64.
Summary
Nanobiotix priced its oversubscribed global offering, raising $98.6 million at a discount to market, which is expected to fund operations into 2029.
Key Events · Financing and Capital Events · NBTX
-
Global Offering Priced
Nanobiotix priced its global follow-on offering, consisting of ADSs and ordinary shares, at $38.98 per ADS and €33.60 per ordinary share. This represents a 14.92% discount to the three-day volume-weighted average price.
-
$98.6 Million Capital Raised
The offering is expected to generate approximately $98.6 million in gross proceeds, with a potential increase to $100 million if the over-allotment option is fully exercised.
-
Cash Runway Extended to 2029
The company anticipates that the net proceeds, combined with existing cash, will be sufficient to fund operations and meet working capital requirements into 2029.
-
Oversubscribed with Shareholder Support
The offering was oversubscribed and received support from existing major shareholders, including Qatar Holding LLC and Invus, as well as other healthcare specialist investors.
Analysis · NBTX · Life Sciences
Nanobiotix has finalized the terms of its global follow-on offering, successfully raising $98.6 million. This capital infusion is critical for the company, extending its cash runway into 2029 and supporting the advancement of its nanotechnology platforms and JNJ-1900 development. While the offering was priced at a 14.92% discount to the three-day volume-weighted average price, the oversubscribed nature and support from existing major shareholders like Qatar Holding LLC and Invus demonstrate confidence in the company's long-term prospects despite the dilutive impact on existing shareholders.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 36.1% of the 1051 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.56%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, NBTX was trading at $40.18 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.1B. The 52-week trading range was $3.64 to $57.14. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.